April 22nd 2024
This breakthrough therapy designation of ziftomenib marks the first of its kinds in NPM1-mutant acute myeloid leukemia.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Gilteritinib as Maintenance Shows Benefit in MRD+ FLT3-Mutant AML Post HCT
June 12th 2023In patients with FLT3-ITD–mutant acute myeloid leukemia and detectable minimal residual disease after hematopoietic stem cell transplant, treatment with gilteritinib elicited a 48% reduction vs patients without detectable MRD.
Read More
FDA Lifts Partial Clinical Hold on Study of FHD-286 in R/R AML, MDS
June 8th 2023Now that the FDA has lifted the partial clinical hold on the phase 1 study of FHD-286 in patients with relapsed/refractory acute myelogenous leukemia and myelodysplastic syndrome, there are plans to initiate a trial to further assess the agent with decitabine or cytarabine.
Read More
Voruciclib +/- Venetoclax Yeilds Promising Efficacy in AML or B-Cell Malignancies
May 25th 2023When used as a monotherapy or in combination with venetoclax, voruciclib was generally well tolerated and showed an encouraging preliminary efficacy signal in patients with acute myeloid leukemia or B-cell malignancies.
Read More
Phase 3 Study of Uproleselan for R/R AML to Continue to Final OS Events Trigger
February 15th 2023The independent Data Monitoring Committee recommends the phase 3 study evaluating treatment with uproleselan in patients with relapsed/refractory acute myeloid leukemia to continue to the original planned final overall survival events trigger.
Read More
No Survival Advantage When Chemotherapy Is Given Prior to Transplant in R/R AML
February 14th 2023In the phase 3 ETAL3-ASAP trial, patients with relapsed/refractory acute myeloid leukemia given an allogeneic hematopoietic cell transplant had similar overall survival rates vs those given intense salvage chemotherapy first.
Read More
Phase 2 KOMET-001 Trial of Ziftomenib Begins Dosing Patients With NPM1-Mutant AML
February 10th 2023In phase 1 of the KOMET-001 trial, ziftomenib showed a 30% complete response rate in patients with NPM1-mutant acute myeloid leukemia treated at a dose of 600 mg. This is now the recommended phase 2 dose for the phase 2 portion of the study.
Read More